agree guys
I like this ... it makes me very optimistic about potential for significantly reduced phase III cost.
"Based on discussions with the FDA, instead of running a 120 patient trial as was considered at one stage, the company may only need to conduct a randomised 60 patient trial, with 35 in a treatment arm and 25 in a standard of care arm ( e.g. second line therapy that includes a platinum based drug and taxol). The trial is likely to require 15 sites in the US and 15 sites in Australia and New Zealand. While the primary endpoints have yet to be made known, they will not include stabilization of CA125 biomarker levels as occurred in the Phase II trial.
The trial is likely to commence as a Phase IIb and roll into a Phase III trial. The company anticipates receiving the IND acceptance by June with enrollments to commence in the September quarter."
from Bioshares April 2009 ...
http://www.primabiomed.com.au/projects/prodDocuments/Bioshares308.pdf
- Forums
- ASX - By Stock
- IMM
- north american investment partners
north american investment partners, page-6
-
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
(20min delay)
|
|||||
Last
30.0¢ |
Change
-0.005(1.64%) |
Mkt cap ! $436.3M |
Open | High | Low | Value | Volume |
30.5¢ | 31.3¢ | 30.0¢ | $960.6K | 3.161M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
14 | 188729 | 30.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
31.0¢ | 46153 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 76315 | 0.300 |
11 | 188158 | 0.295 |
13 | 374153 | 0.290 |
7 | 1039385 | 0.285 |
9 | 253967 | 0.280 |
Price($) | Vol. | No. |
---|---|---|
0.310 | 4426 | 1 |
0.315 | 57600 | 2 |
0.320 | 165083 | 4 |
0.325 | 239547 | 4 |
0.330 | 68045 | 5 |
Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |